RS58039B1 - Oralno doziranje glp-1 jedinjenja - Google Patents
Oralno doziranje glp-1 jedinjenjaInfo
- Publication number
- RS58039B1 RS58039B1 RS20181145A RSP20181145A RS58039B1 RS 58039 B1 RS58039 B1 RS 58039B1 RS 20181145 A RS20181145 A RS 20181145A RS P20181145 A RSP20181145 A RS P20181145A RS 58039 B1 RS58039 B1 RS 58039B1
- Authority
- RS
- Serbia
- Prior art keywords
- glp
- compounds
- oral dosing
- dosing
- oral
- Prior art date
Links
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13166205 | 2013-05-02 | ||
PCT/EP2014/058974 WO2014177683A1 (en) | 2013-05-02 | 2014-05-02 | Oral dosing of glp-1 compounds |
EP14721834.1A EP2991671B1 (en) | 2013-05-02 | 2014-05-02 | Oral dosing of glp-1 compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
RS58039B1 true RS58039B1 (sr) | 2019-02-28 |
Family
ID=48190381
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20181145A RS58039B1 (sr) | 2013-05-02 | 2014-05-02 | Oralno doziranje glp-1 jedinjenja |
Country Status (24)
Country | Link |
---|---|
US (3) | US20160067184A1 (sr) |
EP (2) | EP3485900A1 (sr) |
JP (2) | JP6672140B2 (sr) |
KR (3) | KR20180115814A (sr) |
AU (1) | AU2014261336B2 (sr) |
BR (1) | BR112015026325A2 (sr) |
CA (1) | CA2910903A1 (sr) |
CY (1) | CY1120730T1 (sr) |
DK (1) | DK2991671T3 (sr) |
ES (1) | ES2688462T3 (sr) |
HR (1) | HRP20181393T1 (sr) |
HU (1) | HUE040609T2 (sr) |
IL (1) | IL241813A (sr) |
LT (1) | LT2991671T (sr) |
MX (3) | MX369259B (sr) |
MY (1) | MY172578A (sr) |
PL (1) | PL2991671T3 (sr) |
PT (1) | PT2991671T (sr) |
RS (1) | RS58039B1 (sr) |
RU (1) | RU2671406C2 (sr) |
SA (1) | SA515370075B1 (sr) |
SI (1) | SI2991671T1 (sr) |
WO (1) | WO2014177683A1 (sr) |
ZA (2) | ZA201507096B (sr) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2600440C3 (ru) | 2010-12-16 | 2021-12-10 | Ново Нордиск А/С | Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты |
PT2696687T (pt) | 2011-04-12 | 2017-02-02 | Novo Nordisk As | Derivados de glp-1 duplamente acilados |
ES2690553T3 (es) | 2012-03-22 | 2018-11-21 | Novo Nordisk A/S | Composiciones de péptidos GLP-1 y preparación de estas |
JP6356660B2 (ja) | 2012-03-22 | 2018-07-11 | ノヴォ ノルディスク アー/エス | 送達剤を含む組成物およびその調製 |
DK2827845T3 (en) | 2012-03-22 | 2019-04-01 | Novo Nordisk As | COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF |
CN104487056A (zh) | 2012-06-20 | 2015-04-01 | 诺和诺德A/S(股份有限公司) | 包含肽和递送剂的片剂制剂 |
MX369259B (es) | 2013-05-02 | 2019-11-04 | Novo Nordisk As | Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1). |
KR102294577B1 (ko) | 2015-01-12 | 2021-08-26 | 엔터리스 바이오파마, 인크. | 고체 경구 제형 |
WO2016168388A2 (en) | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
US11196462B2 (en) | 2016-02-22 | 2021-12-07 | Qualcomm Incorporated | Multi-layer beamforming in millimeter-wave multiple-input/multiple-output systems |
PE20211202A1 (es) | 2017-08-24 | 2021-07-05 | Novo Nordisk As | Composiciones de glp-1 y sus usos |
SG11202002841PA (en) * | 2017-10-12 | 2020-04-29 | Novo Nordisk As | Semaglutide in medical therapy |
MX2020004497A (es) * | 2017-10-31 | 2020-08-13 | Medimmune Ltd | Administracion oral de analogos del peptido glp-1. |
ES2960687T3 (es) | 2018-02-02 | 2024-03-06 | Novo Nordisk As | Composiciones sólidas que comprenden un agonista del GLP-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico y un lubricante |
TWI829687B (zh) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
CA3107345A1 (en) | 2018-07-23 | 2020-01-30 | Eli Lilly And Company | Gip/glp1 co-agonist compounds |
US11471512B2 (en) * | 2019-03-01 | 2022-10-18 | Merck Sharp & Dohme Llc | Pharmaceutical compositions of a peptide |
WO2021089752A1 (en) | 2019-11-07 | 2021-05-14 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
TW202140063A (zh) | 2020-02-18 | 2021-11-01 | 丹麥商諾佛 儂迪克股份有限公司 | 醫藥配方 |
EP4142695A1 (en) | 2020-04-29 | 2023-03-08 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist and histidine |
JP2023534130A (ja) * | 2020-07-22 | 2023-08-08 | ノヴォ ノルディスク アー/エス | Glp-1受容体およびgip受容体共作動薬 |
BR112023000270A2 (pt) | 2020-07-22 | 2023-01-31 | Novo Nordisk As | Composto, composição farmacêutica, e, peptídeo |
EP4360645A1 (en) * | 2021-06-25 | 2024-05-01 | Gan & Lee Pharmaceuticals Co., Ltd. | Pharmaceutical composition containing glp-1 compound |
KR20230010571A (ko) | 2021-07-12 | 2023-01-19 | 한미약품 주식회사 | Glp-1 유사체를 함유하는 경구 투여 제형 조성물 |
KR20240036563A (ko) | 2021-07-15 | 2024-03-20 | 노보 노르디스크 에이/에스 | N-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 정제 |
WO2023065231A1 (en) * | 2021-10-21 | 2023-04-27 | Guangzhou Dazhou Biomedicine Ltd. | Oral delivery of therapeutic agents |
WO2023123063A1 (en) * | 2021-12-29 | 2023-07-06 | Guangzhou Dazhou Biomedicine Ltd. | Oral delivery |
TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
KR20230132256A (ko) | 2022-03-08 | 2023-09-15 | 이정열 | 오징어 조획장치 |
KR20230147981A (ko) | 2022-04-15 | 2023-10-24 | 이정열 | 어류 탈취기 |
KR20230167546A (ko) | 2022-06-02 | 2023-12-11 | 이정열 | 어류 탈취기 |
KR20240018118A (ko) | 2022-08-02 | 2024-02-13 | 이정열 | 어류 탈취기 |
WO2024040356A1 (en) * | 2022-08-25 | 2024-02-29 | The University Of British Columbia | Mucoadhesive pharmaceutical dosage form for unidirectional release of peptide therapeutic particles |
KR20240055265A (ko) | 2022-10-20 | 2024-04-29 | 이정열 | 어류 탈취기 |
WO2024110614A1 (en) * | 2022-11-25 | 2024-05-30 | Novo Nordisk A/S | Oral administration of peptide therapeutics, such as glp-1 |
WO2024141760A1 (en) | 2022-12-30 | 2024-07-04 | Algipharma As | Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
EP1149066B1 (en) | 1999-02-05 | 2005-11-09 | Emisphere Technologies, Inc. | Method of preparing alkylated salicylamides |
AU775063C (en) | 1999-04-30 | 2005-05-12 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
AU2001275231A1 (en) | 2000-06-02 | 2001-12-11 | Emisphere Technologies, Inc. | Method of preparing salicylamides |
AU2002228608A1 (en) | 2000-12-13 | 2002-06-24 | Eli Lilly And Company | Amidated glucagon-like peptide-1 |
CN1501809B (zh) * | 2000-12-13 | 2012-10-10 | 伊莱利利公司 | 应用胰高血糖素样促胰岛肽的长期治疗方案 |
PL209734B1 (pl) | 2002-02-20 | 2011-10-31 | Emisphere Tech Inc | Preparat farmaceutyczny zawierający związek GLP-1 i czynnik dostarczający oraz jego zastosowanie |
ES2327328T3 (es) | 2002-07-04 | 2009-10-28 | Zealand Pharma A/S | Glp-1 y procedimientos para el tratamiento de la diabetes. |
WO2005014049A2 (en) | 2003-08-08 | 2005-02-17 | Novo Nordisk A/S | Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides |
TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
PL2347762T3 (pl) | 2005-08-19 | 2019-09-30 | Amylin Pharmaceuticals, Llc | Eksendyna do leczenia cukrzycy i zmniejszania masy ciała |
WO2007061434A2 (en) | 2005-11-10 | 2007-05-31 | Nastech Pharmaceutical Company Inc. | A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome |
JP2009520693A (ja) | 2005-12-08 | 2009-05-28 | エムディーアールエヌエー,インコーポレイテッド | 安定化されたエキセンディン製剤の粘膜送達 |
WO2007121318A2 (en) | 2006-04-12 | 2007-10-25 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
JP5021033B2 (ja) | 2006-09-07 | 2012-09-05 | エフ.ホフマン−ラ ロシュ アーゲー | Snac(サルカプロザートナトリウム)の製造法 |
CL2007002634A1 (es) * | 2006-09-13 | 2008-05-16 | Smithkline Beecham Corp | Uso de una composicion que comprende al menos un polipeptido que tiene actividad de peptido-1 semejante a glucagon (glp-1) como agente hipoglucemiante de larga duracion. |
HUE029512T2 (en) | 2006-09-22 | 2017-03-28 | Novo Nordisk As | Protease Resistant Insulin Analogs |
CN101868476B (zh) | 2007-09-05 | 2015-02-25 | 诺沃-诺迪斯克有限公司 | 胰高血糖素样肽-1衍生物及其制药用途 |
US20100317057A1 (en) | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
RU2494755C2 (ru) | 2008-08-18 | 2013-10-10 | Интера Био Лтд. | Способы и композиции для перорального введения белков |
EP2340049B1 (en) | 2008-09-12 | 2015-11-11 | Novo Nordisk A/S | Method of acylating a peptide or protein |
JP6006118B2 (ja) | 2009-12-16 | 2016-10-12 | ノヴォ ノルディスク アー/エス | Glp−1アナログ及び誘導体 |
CN102869676A (zh) * | 2010-04-30 | 2013-01-09 | 株式会社三和化学研究所 | 用于提高生理活性物质等的生物体内稳定性的肽和提高了生物体内稳定性的生理活性物质 |
RU2600440C3 (ru) | 2010-12-16 | 2021-12-10 | Ново Нордиск А/С | Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты |
PT2696687T (pt) * | 2011-04-12 | 2017-02-02 | Novo Nordisk As | Derivados de glp-1 duplamente acilados |
JP6006309B2 (ja) * | 2011-07-08 | 2016-10-12 | アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals,Llc | 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド |
ES2690553T3 (es) * | 2012-03-22 | 2018-11-21 | Novo Nordisk A/S | Composiciones de péptidos GLP-1 y preparación de estas |
JP6356660B2 (ja) | 2012-03-22 | 2018-07-11 | ノヴォ ノルディスク アー/エス | 送達剤を含む組成物およびその調製 |
CN104487056A (zh) * | 2012-06-20 | 2015-04-01 | 诺和诺德A/S(股份有限公司) | 包含肽和递送剂的片剂制剂 |
MX369259B (es) | 2013-05-02 | 2019-11-04 | Novo Nordisk As | Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1). |
-
2014
- 2014-05-02 MX MX2015015009A patent/MX369259B/es active IP Right Grant
- 2014-05-02 JP JP2016511088A patent/JP6672140B2/ja active Active
- 2014-05-02 PT PT14721834T patent/PT2991671T/pt unknown
- 2014-05-02 KR KR1020187029869A patent/KR20180115814A/ko not_active Application Discontinuation
- 2014-05-02 EP EP18188817.3A patent/EP3485900A1/en active Pending
- 2014-05-02 EP EP14721834.1A patent/EP2991671B1/en not_active Revoked
- 2014-05-02 DK DK14721834.1T patent/DK2991671T3/en active
- 2014-05-02 CA CA2910903A patent/CA2910903A1/en not_active Withdrawn
- 2014-05-02 AU AU2014261336A patent/AU2014261336B2/en active Active
- 2014-05-02 WO PCT/EP2014/058974 patent/WO2014177683A1/en active Application Filing
- 2014-05-02 SI SI201430880T patent/SI2991671T1/sl unknown
- 2014-05-02 US US14/785,493 patent/US20160067184A1/en not_active Abandoned
- 2014-05-02 BR BR112015026325A patent/BR112015026325A2/pt not_active Application Discontinuation
- 2014-05-02 MY MYPI2015703259A patent/MY172578A/en unknown
- 2014-05-02 RS RS20181145A patent/RS58039B1/sr unknown
- 2014-05-02 HU HUE14721834A patent/HUE040609T2/hu unknown
- 2014-05-02 ES ES14721834.1T patent/ES2688462T3/es active Active
- 2014-05-02 KR KR1020157032843A patent/KR102272671B1/ko active IP Right Grant
- 2014-05-02 RU RU2015147876A patent/RU2671406C2/ru active
- 2014-05-02 LT LTEP14721834.1T patent/LT2991671T/lt unknown
- 2014-05-02 KR KR1020217020196A patent/KR20210086717A/ko not_active Application Discontinuation
- 2014-05-02 PL PL14721834T patent/PL2991671T3/pl unknown
-
2015
- 2015-09-24 IL IL241813A patent/IL241813A/en active IP Right Grant
- 2015-09-25 ZA ZA2015/07096A patent/ZA201507096B/en unknown
- 2015-10-27 MX MX2018012166A patent/MX2018012166A/es unknown
- 2015-10-27 MX MX2019013123A patent/MX2019013123A/es unknown
- 2015-10-29 SA SA515370075A patent/SA515370075B1/ar unknown
-
2017
- 2017-07-17 US US15/651,043 patent/US10278923B2/en active Active
-
2018
- 2018-08-29 HR HRP20181393TT patent/HRP20181393T1/hr unknown
- 2018-10-08 CY CY181101036T patent/CY1120730T1/el unknown
- 2018-10-12 ZA ZA2018/06791A patent/ZA201806791B/en unknown
-
2019
- 2019-03-22 US US16/361,971 patent/US20190216739A1/en active Pending
- 2019-12-25 JP JP2019235054A patent/JP2020073533A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201806791B (en) | Oral dosing of glp-1 compounds | |
GB201322602D0 (en) | Pharmaceutical compounds | |
HRP20181607T1 (hr) | Stabilne oralne otopine za kombinirane aktivne farmaceutske sastojke | |
GB201306610D0 (en) | Pharmaceutical compounds | |
IL244380A0 (en) | Pharmaceutical compounds | |
GB201312386D0 (en) | Pharmaceutical compounds | |
EP2948129A4 (en) | THERAPEUTIC COMPOUNDS | |
GB201305103D0 (en) | An oral dosage form | |
GB201413253D0 (en) | Solid dosage form | |
GB201314286D0 (en) | Therapeutic Compounds | |
GB201312499D0 (en) | Therapeutic compounds | |
GB2520315B (en) | Oral Syringes | |
GB201407847D0 (en) | Composition for the oral delivery of compounds | |
GB201320905D0 (en) | Therapeutic compounds | |
GB201314397D0 (en) | Therapeutic Compounds | |
GB201311169D0 (en) | Therapeutic compounds | |
GB201317166D0 (en) | Pharmaceutical compounds | |
GB201316780D0 (en) | Pharmaceutical compounds | |
GB201316791D0 (en) | Pharmaceutical Compounds | |
GB201315733D0 (en) | Pharmaceutical compounds | |
GB201315734D0 (en) | Pharmaceutical compounds | |
GB201312464D0 (en) | Pharmaceutical compounds | |
GB201308782D0 (en) | Pharmaceutical compounds | |
GB201308781D0 (en) | Pharmaceutical compounds | |
GB201308780D0 (en) | Pharmaceutical compounds |